PL2010209T3 - Immunogeniczne peptydy WT-1 i sposoby ich użycia - Google Patents

Immunogeniczne peptydy WT-1 i sposoby ich użycia

Info

Publication number
PL2010209T3
PL2010209T3 PL07755205T PL07755205T PL2010209T3 PL 2010209 T3 PL2010209 T3 PL 2010209T3 PL 07755205 T PL07755205 T PL 07755205T PL 07755205 T PL07755205 T PL 07755205T PL 2010209 T3 PL2010209 T3 PL 2010209T3
Authority
PL
Poland
Prior art keywords
immunogenic
peptides
methods
Prior art date
Application number
PL07755205T
Other languages
English (en)
Inventor
A. SCHEINBERG David
Rena May
Original Assignee
Sloan Kettering Inst For Cancer Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sloan Kettering Inst For Cancer Res filed Critical Sloan Kettering Inst For Cancer Res
Publication of PL2010209T3 publication Critical patent/PL2010209T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001152—Transcription factors, e.g. SOX or c-MYC
    • A61K39/001153—Wilms tumor 1 [WT1]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/19—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4242—Transcription factors, e.g. SOX or c-MYC
    • A61K40/4243—Wilms tumor 1 [WT1]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/428—Undefined tumor antigens, e.g. tumor lysate or antigens targeted by cells isolated from tumor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/868—Vaccine for a specifically defined cancer kidney
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
PL07755205T 2006-04-10 2007-04-10 Immunogeniczne peptydy WT-1 i sposoby ich użycia PL2010209T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US79052606P 2006-04-10 2006-04-10
US85200906P 2006-10-17 2006-10-17

Publications (1)

Publication Number Publication Date
PL2010209T3 true PL2010209T3 (pl) 2017-04-28

Family

ID=38610136

Family Applications (1)

Application Number Title Priority Date Filing Date
PL07755205T PL2010209T3 (pl) 2006-04-10 2007-04-10 Immunogeniczne peptydy WT-1 i sposoby ich użycia

Country Status (6)

Country Link
US (4) US9265816B2 (pl)
EP (3) EP2010209B1 (pl)
CA (1) CA2645766A1 (pl)
ES (1) ES2591029T3 (pl)
PL (1) PL2010209T3 (pl)
WO (1) WO2007120673A2 (pl)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100513563C (zh) 2003-11-05 2009-07-15 株式会社国际癌症免疫研究所 Wt1衍生的hla-dr-结合抗原肽
WO2007047764A2 (en) * 2005-10-17 2007-04-26 Sloan Kettering Institute For Cancer Research Wt1 hla class ii-binding peptides and compositions and methods comprising same
US9732131B2 (en) 2006-02-27 2017-08-15 Calviri, Inc. Identification and use of novopeptides for the treatment of cancer
EP2010209B1 (en) 2006-04-10 2016-06-15 Sloan Kettering Institute For Cancer Research Immunogenic wt-1 peptides and methods of use thereof
CA2677075C (en) 2007-02-27 2018-07-10 International Institute Of Cancer Immunology, Inc. Method for activation of helper t cell and composition for use in the method
WO2009066462A1 (ja) * 2007-11-20 2009-05-28 Nec Corporation 細胞傷害性ｔ細胞の誘導方法、細胞傷害性ｔ細胞の誘導剤、およびそれを用いた医薬組成物およびワクチン
NZ609460A (en) 2010-10-05 2015-07-31 Otsuka Pharma Co Ltd Method for activating helper t cell
EP2792745B1 (en) * 2011-12-14 2017-11-15 National University Corporation Kochi University Modification of helper t cell-inducing polypeptide
CN104684577B (zh) 2012-01-13 2018-05-08 纪念斯隆凯特林癌症中心 免疫原性wt-1肽及其使用方法
CA2892660C (en) * 2012-12-17 2022-02-15 Otsuka Pharmaceutical Co., Ltd. Method for activating helper t cell
US10815273B2 (en) 2013-01-15 2020-10-27 Memorial Sloan Kettering Cancer Center Immunogenic WT-1 peptides and methods of use thereof
EP3769782A1 (en) * 2013-01-15 2021-01-27 Memorial Sloan Kettering Cancer Center Immunogenic wt-1 peptides and methods of use thereof
EP2980097A4 (en) 2013-03-29 2017-03-08 Sumitomo Dainippon Pharma Co., Ltd. Conjugate vaccine using trimming function of erap1
EP3461493A1 (en) 2013-03-29 2019-04-03 Sumitomo Dainippon Pharma Co., Ltd. Wt1 antigen peptide conjugate vaccine
EP3377516B1 (en) 2015-11-20 2022-06-15 Memorial Sloan Kettering Cancer Center Composition for treating cancer
JP7209963B2 (ja) 2016-11-30 2023-01-23 住友ファーマ株式会社 Ｗｔ１ヘルパーペプチド及びこれと癌抗原ペプチドコンジュゲート体との組合せ
WO2018181648A1 (ja) 2017-03-30 2018-10-04 大日本住友製薬株式会社 Ｗｔ１癌抗原ペプチドおよびこれを含むペプチドコンジュゲート体
US11484581B2 (en) 2017-06-02 2022-11-01 Arizona Board Of Regents On Behalf Of Arizona State University Method to create personalized canine cancer vaccines
US12025615B2 (en) 2017-09-15 2024-07-02 Arizona Board Of Regents On Behalf Of Arizona State University Methods of classifying response to immunotherapy for cancer
KR20210068060A (ko) 2018-09-28 2021-06-08 다이니뽄 스미토모 세이야쿠 가부시키가이샤 주사용 조성물
TWI875736B (zh) 2019-02-28 2025-03-11 日商住友製藥股份有限公司 選擇可期待用於治療或預防癌之醫藥組合物之效果之對象之方法
EP4038222A4 (en) 2019-10-02 2023-10-18 Arizona Board of Regents on behalf of Arizona State University Methods and compositions for identifying neoantigens for use in treating and preventing cancer
CN115867303A (zh) 2020-05-12 2023-03-28 住友制药株式会社 用于治疗癌症的药物组合物
EP4385519A4 (en) 2021-08-12 2025-08-06 Int Inst Cancer Immunology Inc PHARMACEUTICAL COMPOSITION AND METHOD FOR TREATING OR PREVENTING CANCER

Family Cites Families (117)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4722848A (en) 1982-12-08 1988-02-02 Health Research, Incorporated Method for immunizing animals with synthetically modified vaccinia virus
US5837249A (en) 1985-04-19 1998-11-17 The Wistar Institute Method for generating an immunogenic T cell response protective against a virus
US5726288A (en) 1989-11-13 1998-03-10 Massachusetts Institute Of Technology Localization and characterization of the Wilms' tumor gene
US5229115A (en) 1990-07-26 1993-07-20 Immunex Corporation Adoptive immunotherapy with interleukin-7
WO1992013878A2 (en) 1991-02-07 1992-08-20 Board Of Trustees Of The University Of Illinois Conformationally restricted mimetics of beta turns and beta bulges and peptides containing the same
CA2158281A1 (en) 1993-03-15 1994-09-29 Jay A. Berzofsky Peptide coated dendritic cells as immunogens
AU2392795A (en) 1994-04-22 1995-11-16 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Isolation and characterization of a novel primate t-cell lymphotropic virus and the use of this virus or components thereof in diagnostics assays and vaccines
US5622835A (en) 1994-04-28 1997-04-22 The Wistar Institute Of Anatomy & Biology WT1 monoclonal antibodies
US5643786A (en) 1995-01-27 1997-07-01 The United States Of America As Represented By The Department Of Health And Human Services Method for isolating dendritic cells
US6156316A (en) 1995-05-08 2000-12-05 Sloan-Kettering Institute For Cancer Research Oncogene fusion protein peptide vaccines
JPH11171896A (ja) 1995-09-19 1999-06-29 Kirin Brewery Co Ltd 新規ペプチド化合物およびその医薬組成物
US5981217A (en) 1995-12-11 1999-11-09 Mayo Foundation For Medical Education And Research DNA encoding TGF-β inducible early factor-1 (TIEF-1), a gene expressed by osteoblasts
ES2203782T3 (es) 1996-01-17 2004-04-16 Imperial College Innovations Limited Inmunoterapia que utiliza linfocitos t citotoxicos (ctl).
US5853719A (en) 1996-04-30 1998-12-29 Duke University Methods for treating cancers and pathogen infections using antigen-presenting cells loaded with RNA
US6207375B1 (en) 1996-12-11 2001-03-27 Mayo Foundation For Medical Educational & Research TGF-β inducible early factor-1 (TIEF-1) and a method to detect breast cancer
ID27813A (id) 1998-01-28 2001-04-26 Corixa Corp Senyawa-senyawa untuk terapi dan diagnosa kanker paru-paru dan metoda untuk penggunaannya
BRPI9912663B8 (pt) 1998-07-31 2021-07-06 Int Inst Cancer Immunology Inc vacina contra cáncer e polipeptìdeo.
US20120301492A1 (en) 1998-09-30 2012-11-29 Corixa Corporation Compositions and methods for wt1 specific immunotherapy
US7329410B1 (en) 1998-09-30 2008-02-12 Corixa Corporation Compositions and method for WT1 specific immunotherapy
US7144581B2 (en) 2000-10-09 2006-12-05 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US7063854B1 (en) 1998-09-30 2006-06-20 Corixa Corporation Composition and methods for WTI specific immunotherapy
US7901693B2 (en) 1998-09-30 2011-03-08 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US20030235557A1 (en) 1998-09-30 2003-12-25 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US20030072767A1 (en) * 1998-09-30 2003-04-17 Alexander Gaiger Compositions and methods for WT1 specific immunotherapy
US7655249B2 (en) * 1998-09-30 2010-02-02 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US7115272B1 (en) 1998-09-30 2006-10-03 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
GB9823897D0 (en) 1998-11-02 1998-12-30 Imp College Innovations Ltd Immunotherapeutic methods and molecules
KR20010080757A (ko) * 1998-12-18 2001-08-22 추후보정 융모막 성선자극호르몬 ｄｎａ 백신 및 방법
WO2000037491A2 (en) 1998-12-22 2000-06-29 Genset Dnas encoding proteins with signal sequences
AU3395900A (en) 1999-03-12 2000-10-04 Human Genome Sciences, Inc. Human lung cancer associated gene sequences and polypeptides
CA2367692A1 (en) 1999-03-15 2000-09-21 Introgen Therapeutics, Inc. Dendritic cells transduced with a wild-type self gene elicit potent antitumor immune responses
US6593299B1 (en) 1999-04-21 2003-07-15 University Of Florida Research Foundation, Inc. Compositions and methods for controlling pests
WO2001025273A2 (en) 1999-10-04 2001-04-12 Corixa Corporation Compositions and methods for wt1 specific immunotherapy
US20030082194A1 (en) 2000-02-22 2003-05-01 Alexander Gaiger Compositions and methods for diagnosis and therapy of malignant mesothelioma
EP1261711A2 (en) 2000-02-22 2002-12-04 Corixa Corporation Compositions and methods for diagnosis and therapy of malignant mesothelioma
US20040002068A1 (en) 2000-03-01 2004-01-01 Corixa Corporation Compositions and methods for the detection, diagnosis and therapy of hematological malignancies
US6861234B1 (en) 2000-04-28 2005-03-01 Mannkind Corporation Method of epitope discovery
EP1209226A3 (en) 2000-11-07 2002-06-05 GSF-Forschungszentrum für Umwelt und Gesundheit GmbH Maturation of dendritic cells by recombinant heat shock protein 70 (hsp70)
US20040053822A1 (en) * 2000-12-11 2004-03-18 John Fikes Inducing cellular immune responses to mage2/3 using peptide and nucleic acid compositions
EP1371664B1 (en) 2001-03-22 2008-01-09 International Institute of Cancer Immunology, Inc. Wti modified peptide
US8771702B2 (en) 2001-03-26 2014-07-08 The Trustees Of The University Of Pennsylvania Non-hemolytic LLO fusion proteins and methods of utilizing same
US20060165708A1 (en) 2001-06-29 2006-07-27 Chugai Seiyaku Kabushiki Kaisha Cancer vaccine containing cancer antigen based on tumor suppressor gene wt1 product and cationic liposomes
US7553494B2 (en) 2001-08-24 2009-06-30 Corixa Corporation WT1 fusion proteins
WO2003028757A1 (en) 2001-09-28 2003-04-10 Haruo Sugiyama Novel method of inducing antigen-specific t cells
JPWO2003028758A1 (ja) 2001-09-28 2005-01-13 治夫 杉山 抗原特異的ｔ細胞の誘導方法
US20030072761A1 (en) 2001-10-16 2003-04-17 Lebowitz Jonathan Methods and compositions for targeting proteins across the blood brain barrier
US20030175272A1 (en) 2002-03-07 2003-09-18 Medcell Biologics, Inc. Re-activated T-cells for adoptive immunotherapy
ATE466084T1 (de) 2002-06-12 2010-05-15 Int Inst Cancer Immunology Inc Hla-a24-restringiertes krebsantigenpeptid
WO2004084936A2 (en) 2003-02-06 2004-10-07 Cerus Corporation Modified free-living microbes, vaccine compositions and methods of use thereof
US20050008618A1 (en) 2003-02-27 2005-01-13 Howard Kaufman Composition for delivering an agent to a target cell and uses thereof
CA2514288C (en) 2003-03-05 2015-07-07 Dendreon Corporation Compositions and methods employing alternative reading frame polypeptides for the treatment of cancer and infectious disease
EP1640458B1 (en) 2003-06-27 2011-12-28 International Institute of Cancer Immunology, Inc. Method of selecting patients suitable for wt1 vaccine
US20050147621A1 (en) 2003-10-10 2005-07-07 Higgins Darren E. Use of bacterial 5' untranslated regions for nucleic acid expression
CN100513563C (zh) 2003-11-05 2009-07-15 株式会社国际癌症免疫研究所 Wt1衍生的hla-dr-结合抗原肽
AU2004294345B2 (en) * 2003-12-01 2012-02-23 Sloan-Kettering Institute For Cancer Research Synthetic HLA binding peptide analogues and uses thereof
ES2484340T3 (es) 2003-12-05 2014-08-11 Multimmune Gmbh Anticuerpos anti hsp70 terapéuticos y diagnósticos
EP1550458A1 (en) 2003-12-23 2005-07-06 Vectron Therapeutics AG Synergistic liposomal adjuvants
WO2005087260A1 (en) 2004-03-04 2005-09-22 Corixa Corporation Co-encapsulated wt1 polypeptide and immunostimulant microsphere formulations and methods thereof
US20050214268A1 (en) 2004-03-25 2005-09-29 Cavanagh William A Iii Methods for treating tumors and cancerous tissues
US20050221481A1 (en) 2004-03-30 2005-10-06 Istituto Superiore Di Sanita' Amplification of T cells from human cord blood in serum-deprived culture stimulated with stem cell factor, interleukin-7 and interleukin-2
SI1731605T1 (sl) 2004-03-31 2010-07-30 Internat Inst Of Cancer Immunolog Inc Peptidi antigena karcinoma izvedeni iz WT1
US9629927B2 (en) 2005-07-29 2017-04-25 Sloan-Kettering Institute For Cancer Research Single wall nanotube constructs and uses thereof
WO2007047764A2 (en) 2005-10-17 2007-04-26 Sloan Kettering Institute For Cancer Research Wt1 hla class ii-binding peptides and compositions and methods comprising same
SI1961761T1 (sl) 2005-11-30 2010-12-31 Int Inst Cancer Immunology Inc Nove peptidne spojine iz Wilmsovega tumorja
CN101384716B (zh) 2006-02-22 2013-03-13 株式会社癌免疫研究所 Hla-a*3303限制性wt1肽和包含此肽的药物组合物
ES2387999T3 (es) 2006-03-29 2012-10-05 International Institute Of Cancer Immunology, Inc. ARNsi específico de la isoforma WT1 17AA(-) y uso del mismo
EP2010209B1 (en) 2006-04-10 2016-06-15 Sloan Kettering Institute For Cancer Research Immunogenic wt-1 peptides and methods of use thereof
WO2007120603A2 (en) 2006-04-10 2007-10-25 Sloan Kettering Institute For Cancer Research Immunogenic bcr-abl peptides and methods of use thereof
JP5623747B2 (ja) 2006-12-27 2014-11-12 エモリー ユニバーシティ 感染症および腫瘍を処置するための組成物および方法
CA2886619A1 (en) 2006-12-28 2008-07-10 International Institute Of Cancer Immunology, Inc. Hla-a*1101-restricted wt1 peptide and pharmaceutical composition comprising the same
JP5239041B2 (ja) 2007-02-07 2013-07-17 一般財団法人阪大微生物病研究会 癌の治療剤
CA2677075C (en) 2007-02-27 2018-07-10 International Institute Of Cancer Immunology, Inc. Method for activation of helper t cell and composition for use in the method
TW200911304A (en) 2007-05-24 2009-03-16 Glaxosmithkline Biolog Sa Lyophillised antigen composition
KR100995340B1 (ko) 2007-11-19 2010-11-19 재단법인서울대학교산학협력재단 자연 살해 ｔ 세포의 리간드와 항원을 적재한 단핵구 또는미분화 골수성 세포를 포함하는 백신
EP2228072B1 (en) 2007-12-05 2018-06-13 International Institute of Cancer Immunology, Inc. Cancer vaccine composition
KR100900837B1 (ko) 2007-12-07 2009-06-04 (주)두비엘 리포펩타이드와 폴리(ｉ:ｃ)를 아쥬반트로 포함하는 강력한백신 조성물
KR20110027695A (ko) 2008-05-19 2011-03-16 아두로 바이오테크 Ｐｒｆａ＊ 돌연변이 리스테리아를 포함하는 조성물 및 그것의 사용방법
US20110318380A1 (en) 2008-10-01 2011-12-29 Dako Denmark A/S MHC Multimers in Cancer Vaccines and Immune Monitoring
AR076349A1 (es) 2009-04-23 2011-06-01 Int Inst Cancer Immunology Inc Peptido auxiliar del antigeno del cancer
WO2011059835A2 (en) 2009-11-11 2011-05-19 Quest Diagnostics Investments Incorporated Wt1 mutations for prognosis of myeloproliferative disorders
US20110136141A1 (en) 2009-12-03 2011-06-09 Abbott Laboratories Peptide reagents and method for inhibiting autoantibody antigen binding
WO2011100754A1 (en) 2010-02-15 2011-08-18 The Trustees Of The University Of Pennsylvania Live listeria-based vaccines for central nervous system therapy
EP2608799B1 (en) 2010-08-24 2018-12-12 University of Pittsburgh - Of the Commonwealth System of Higher Education Interleukin-13 receptor alpha 2 peptide-based brain cancer vaccines
NZ609460A (en) 2010-10-05 2015-07-31 Otsuka Pharma Co Ltd Method for activating helper t cell
BR112013022801A2 (pt) 2011-03-11 2019-09-24 Gilead Calistoga Llc combinações de terapia para malignidades hematológicas
CN107238706A (zh) 2011-06-28 2017-10-10 株式会社癌免疫研究所 肽癌抗原‑特异性t细胞的受体基因
EP2738253A4 (en) 2011-07-29 2015-04-22 Riken CELL FOR USE IN IMMUNOTHERAPY WITH A MODIFIED NUCLEIC ACIDIC CONSTRUCTIVE FOR WILMS TUMORGEN PRODUCT OR FRAGMENT THEREOF, METHOD FOR PRODUCING THIS CELL AND NUCLEIC ACIDIC CONCRETE SAID
US9539299B2 (en) 2011-10-27 2017-01-10 International Institute Of Cancer Immunology, Inc. Combination therapy with WT1 peptide vaccine and temozolomide
EP2792745B1 (en) 2011-12-14 2017-11-15 National University Corporation Kochi University Modification of helper t cell-inducing polypeptide
US10501512B2 (en) 2012-04-02 2019-12-10 Modernatx, Inc. Modified polynucleotides
NZ702108A (en) 2012-05-03 2016-09-30 Hutchinson Fred Cancer Res Enhanced affinity t cell receptors and methods for making the same
US20150150975A1 (en) 2012-07-02 2015-06-04 Sumitomo Dainippon Pharma Co., Ltd. Transdermal cancer antigen peptide preparation
EP2911683B1 (en) 2012-10-23 2019-09-25 Ubivac, LLC Allogeneic autophagosome-enriched composition for the treatment of disease
CA2892660C (en) 2012-12-17 2022-02-15 Otsuka Pharmaceutical Co., Ltd. Method for activating helper t cell
CN104968782B (zh) 2012-12-26 2019-09-06 生物科莫公司 利用人副流感2型病毒载体的疫苗
EP3769782A1 (en) 2013-01-15 2021-01-27 Memorial Sloan Kettering Cancer Center Immunogenic wt-1 peptides and methods of use thereof
JP6512567B2 (ja) 2013-02-05 2019-05-15 日東電工株式会社 経皮投与用ｗｔ１ペプチド癌ワクチン組成物
CN103961305B (zh) 2013-02-05 2019-10-18 日东电工株式会社 经皮给予用wt1肽癌症疫苗带状制剂
KR102045029B1 (ko) 2013-02-05 2019-11-14 닛토덴코 가부시키가이샤 점막 투여용 ｗｔ1 펩티드 암 백신 조성물
CN103961307B (zh) 2013-02-05 2019-11-29 日东电工株式会社 经皮给予用wt1肽癌症疫苗组合物
US20140234351A1 (en) 2013-02-14 2014-08-21 Immunocellular Therapeutics, Ltd. Cancer vaccines and vaccination methods
US9663563B2 (en) 2013-03-12 2017-05-30 Sumitomo Dainippon Pharma Co., Ltd. Aqueous liquid composition
MX369709B (es) 2013-03-15 2019-11-19 Univ Pennsylvania Vacunación mejorada contra tirosinasa.
EP3461493A1 (en) 2013-03-29 2019-04-03 Sumitomo Dainippon Pharma Co., Ltd. Wt1 antigen peptide conjugate vaccine
MX364922B (es) 2013-04-25 2019-05-14 Vaximm Ag Vacuna de adn que dirige wt-1 novedosa para inmunoterapia contra cáncer.
ES2954899T3 (es) 2013-05-13 2023-11-27 Int Inst Cancer Immunology Inc Procedimiento para predecir el efecto clínico de una inmunoterapia
US10898555B2 (en) 2013-07-02 2021-01-26 Japanese Foundation For Cancer Research Cellular immunity inducing vaccine
PT3071593T (pt) 2013-11-22 2019-06-27 The Board Of Trustees Of The Univ Of Illionis Recetores das células t de humanos manipulados de alta-afinidade
AU2014365900B2 (en) 2013-12-18 2020-04-09 Vaximm Gmbh Novel MSLN targeting DNA vaccine for cancer immunotherapy
WO2015103602A1 (en) 2014-01-06 2015-07-09 The Trustees Of The University Of Pennsylvania Pd1 and pdl1 antibodies and vaccine combinations and use of same for immunotherapy
SG11201606625RA (en) 2014-02-14 2016-09-29 Immune Design Corp Immunotherapy of cancer through combination of local and systemic immune stimulation
CN106029699B (zh) 2014-02-26 2019-07-19 泰来有限公司 Wt1抗原性多肽和含有该多肽的抗肿瘤剂
US10023841B2 (en) 2014-05-23 2018-07-17 Baylor Research Institute Methods and compositions for treating breast cancer with dendritic cell vaccines
WO2016093326A1 (ja) 2014-12-11 2016-06-16 株式会社癌免疫研究所 血管新生病の免疫療法
CN108350411B (zh) 2015-06-25 2021-06-22 白川利朗 口服肿瘤疫苗
WO2017049074A1 (en) 2015-09-18 2017-03-23 Moderna Therapeutics, Inc. Polynucleotide formulations for use in the treatment of renal diseases
EP3377516B1 (en) * 2015-11-20 2022-06-15 Memorial Sloan Kettering Cancer Center Composition for treating cancer

Also Published As

Publication number Publication date
EP2010209A4 (en) 2010-03-31
US20230265122A1 (en) 2023-08-24
WO2007120673A3 (en) 2008-11-06
EP2010209B1 (en) 2016-06-15
US11414457B2 (en) 2022-08-16
EP2010209A2 (en) 2009-01-07
US20100092522A1 (en) 2010-04-15
EP3117836A1 (en) 2017-01-18
WO2007120673A2 (en) 2007-10-25
ES2591029T3 (es) 2016-11-24
CA2645766A1 (en) 2007-10-25
EP3834836A1 (en) 2021-06-16
US20160368948A1 (en) 2016-12-22
US20190270776A1 (en) 2019-09-05
US9265816B2 (en) 2016-02-23

Similar Documents

Publication Publication Date Title
PL2010209T3 (pl) Immunogeniczne peptydy WT-1 i sposoby ich użycia
IL197501A0 (en) Modifications of cupredoxin derived peptides and methods of use thereof
EP2068898A4 (en) BONE CEMENT AND APPLICATION METHOD THEREFOR
IL205977A0 (en) 5-anilinoimidazopyridines and methods of use
IL196462A0 (en) Substituted acylanilides and methods of use thereof
IL197185A0 (en) Substituted acylanilides and methods of use thereof
EP2021455A4 (en) SYSTEM FOR PREPARING CYTOBLOCS AND METHODS OF USE THEREOF
EP2091588A4 (en) CARDIAL DEVICE AND USE METHOD THEREFOR
IL189602A0 (en) Indenoisoquinolinone analogs and methods of use thereof
IL222947A0 (en) Luminaire and methods of use
EP2054063A4 (en) 4-AMINOCHINAZOLINE DERIVATIVES AND METHOD FOR THEIR USE
EP2191458A4 (en) FINGER-FITTED DEVICES AND METHODS OF USE THEREOF
ZA200905626B (en) Adjuvants and methods of using them
IL206125A0 (en) Azaindolizines and methods of use
ZA200900203B (en) Adjuvants and methods of use
IL194777A0 (en) Hcv coreceptor and methods of use thereof
EP2185719A4 (en) RANTES ANTIBODIES AND METHOD FOR THEIR USE
IL194028A0 (en) Tetrahydropyridothienopyrimidine compounds and methods of use thereof
EP2478005A4 (en) CROSSLINKED CRYSTALS AND CRYSTALS OF PROTEIN A AND METHODS OF USE THEREOF
ZA200905741B (en) Indenoisoquinolinone analogs and methods of use thereof
GB0908868D0 (en) Depsipeptide and their therapeutic use
GB0615635D0 (en) Immunogenic proteins and uses thereof
IL214762A0 (en) Modifications of cupredoxin derives peptides and methods of use thereof
GB0818065D0 (en) Immunogenic peptides and uses thereof
ZA200710950B (en) Lawsonia vaccine and methods of use thereof